ZURICH, July 22, 2026 /PRNewswire/ -- Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to non-dilutive funding for the...
Hence then, the article about neurimmune sells a portion of its royalty interest in cliramitug to royalty pharma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma )
Also on site :
- Black Friday in July? Macy’s Drops Dozens of Summertime Deals, From Under-$100 Tech to Trendy Band Tees
- Walmart’s ‘Vibrant’ $40 Floral Area Rug Is Machine-Washable, Pet-Friendly, and Full of Cottagecore Charm
- Martha Stewart’s ‘Elegant’ and Modern Wooden Desk Is ‘Just the Right Size’ and It’s Now Under $200 at Amazon